Oct 262004
 

While I’m sure there is probably a “better” ABCR drug I think that the most important thing to do is pick one and start as early as possible. What I found very interesting in the last teleconference (and yes I missed the one tonight 🙁 but failed to post to the blog was that the eight year data in on Rebif showed that those who were on the placebo for two years and then immediately began treatment at the 44mcg dose have never “caught up” to those who started right away at either the 22mcg or the 44mcg dose. I guess this should be phrased differently to be the level of disability with those who have been on the medication the entire time is statistically much less than those who started two years later. Which means the two years resulted in additional lesion load that ultimately resulted in quicker and greater disability. For this reason I think it is very important for anyone who can to take the medication to starts as soon as they can. (I also realize they are prohibitively expensive without insurance and sometimes peoples bodies don’t like any of the ABCR drugs).

 Posted by at 9:43 pm

  One Response to “Choosing an ABCR Drug”

  1. (I also realize they are prohibitively expensive without insurance and sometimes peoples bodies don’t like any of the ABCR drugs). MDMHVONPA raises hand to acknowledge the latter statement. I have a new treatment, it’s called ‘Onery old coot’. It is an inherited treatment though. Mom has had MS since 1976 with no treatment. My Great aunt has been using the OOC treatment since the early 50’s and my Godmother (aunt) has been trying it for about 10 years now, but just started on Copax. The synergistic results for her are not being tolerated very well. My OOC treatment has been going on for some time now and seem to be moderately successfull. 😉 On a serious note, if you can tolerate ABCR, do it by all means.

 Leave a Reply

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

(required)

(required)

*